These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38414031)

  • 1. Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants.
    Wang S; Ding P; Shen L; Fan D; Cheng H; Huo J; Wei X; He H; Zhang G
    J Nanobiotechnology; 2024 Feb; 22(1):76. PubMed ID: 38414031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2.
    Ross KA; Kelly S; Phadke KS; Peroutka-Bigus N; Fasina O; Siddoway A; Mallapragada SK; Wannemuehler MJ; Bellaire BH; Narasimhan B
    Acta Biomater; 2024 Jul; 183():318-329. PubMed ID: 38844193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19.
    Zheng B; Peng W; Guo M; Huang M; Gu Y; Wang T; Ni G; Ming D
    Chem Eng J; 2021 Aug; 418():129392. PubMed ID: 33762883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants.
    Wang W; Meng X; Cui H; Zhang C; Wang S; Feng N; Zhao Y; Wang T; Yan F; Xia X
    Int J Biol Macromol; 2024 Apr; 264(Pt 2):130820. PubMed ID: 38484812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine.
    Wang Z; Popowski KD; Zhu D; de Juan Abad BL; Wang X; Liu M; Lutz H; De Naeyer N; DeMarco CT; Denny TN; Dinh PC; Li Z; Cheng K
    Nat Biomed Eng; 2022 Jul; 6(7):791-805. PubMed ID: 35788687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
    Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J
    Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern.
    Yang J; Liu MQ; Liu L; Li X; Xu M; Lin H; Liu S; Hu Y; Li B; Liu B; Li M; Sun Y; Chen YQ; Shi ZL; Yan H
    Cell Mol Immunol; 2022 Nov; 19(11):1279-1289. PubMed ID: 36220993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
    Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
    Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA
    Wu CY; Tseng YC; Kao SE; Wu LY; Hou JT; Yang YC; Hsiao PW; Chen JR
    Antiviral Res; 2023 Dec; 220():105759. PubMed ID: 37984568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants.
    Lei H; Alu A; Yang J; Ren W; He C; Lan T; He X; Yang L; Li J; Wang Z; Song X; Wang W; Lu G; Wei X
    Signal Transduct Target Ther; 2022 May; 7(1):159. PubMed ID: 35581200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.